相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Astrocyte-Derived alpha 7 Nicotinic Receptor Antagonist Kynurenic Acid Controls Extracellular Glutamate Levels in the Prefrontal Cortex
Hui-Qiu Wu et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2010)
L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning
Amy C. Chess et al.
BEHAVIOURAL BRAIN RESEARCH (2009)
Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase
Silvia K. Schmidt et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release
A. Zmarowski et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2009)
Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases
P. H. Tan et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway
Helen J. Ball et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia
Sara K. Olsson et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2009)
On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo
Laura Amori et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Biochemical and Structural Properties of Mouse Kynurenine Aminotransferase III
Qian Han et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Activation of brain interleukin-1β in schizophrenia
J. Soderlund et al.
MOLECULAR PSYCHIATRY (2009)
Mammalian Nicotinic Acetylcholine Receptors: From Structure to Function
Edson X. Albuquerque et al.
PHYSIOLOGICAL REVIEWS (2009)
Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder
Christine L. Miller et al.
SCHIZOPHRENIA RESEARCH (2009)
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Robert Freedman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Functional co-primary measures for clinical trials in schizophrenia: Results from the MATRICS psychometric and standardization study
Michael F. Green et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Galantamine for the treatment of cognitive impairments in people with schizophrenia
Robert W. Buchanan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Refining the predictive pursuit endophenotype in schizophrenia
L. Elliot Hong et al.
BIOLOGICAL PSYCHIATRY (2008)
From inflammation to sickness and depression: when the immune system subjugates the brain
Robert Dantzer et al.
NATURE REVIEWS NEUROSCIENCE (2008)
Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder
Christine L. Miller et al.
NEUROCHEMISTRY INTERNATIONAL (2008)
Realistic expectations of prepulse inhibition in translational models for schizophrenia research
Neal R. Swerdlow et al.
PSYCHOPHARMACOLOGY (2008)
The Cognitive and Negative Symptoms in Schizophrenia, Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments
Robert W. Buchanan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain
Paolo Guidetti et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Elevations of endogenous kynurenic acid produce spatial working memory deficits
Amy C. Chess et al.
SCHIZOPHRENIA BULLETIN (2007)
Schizophrenia endophenotypes as treatment targets
Gunvant K. Thaker
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain
G. Ceresoli-Borroni et al.
JOURNAL OF NEURAL TRANSMISSION (2006)
Galantamine improves cognition in schizophrenic patients stabilized on risperidone
Max H. Schubert et al.
BIOLOGICAL PSYCHIATRY (2006)
Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population
N. Aoyama et al.
GENES BRAIN AND BEHAVIOR (2006)
Effects of repeated amphetamine administration on antisaccades in schizophrenia spectrum personality
I Wonodi et al.
PSYCHIATRY RESEARCH (2006)
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia
LK Nilsson et al.
SCHIZOPHRENIA RESEARCH (2005)
Cognitive predictors of psychosocial functioning outcome in schizophrenia: A follow-up study of subjects participating in a rehabilitation program
A Prouteau et al.
SCHIZOPHRENIA RESEARCH (2005)
A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients
EYH Chen et al.
SCHIZOPHRENIA RESEARCH (2005)
The primacy of cognition in schizophrenia
RW Heinrichs
AMERICAN PSYCHOLOGIST (2005)
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
S Miyamoto et al.
MOLECULAR PSYCHIATRY (2005)
Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia
CL Miller et al.
NEUROBIOLOGY OF DISEASE (2004)
Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking
RF Anton et al.
PSYCHOPHARMACOLOGY (2004)
Endogenous kynurenic acid disrupts prepulse inhibition
S Erhardt et al.
BIOLOGICAL PSYCHIATRY (2004)
Identification of separable cognitive factors in schizophrenia
KH Nuechterlein et al.
SCHIZOPHRENIA RESEARCH (2004)
Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia
SR Marder et al.
SCHIZOPHRENIA RESEARCH (2004)
Direct assessment of functional abilities: relevance to persons with schizophrenia
CL McKibbin et al.
SCHIZOPHRENIA RESEARCH (2004)
Cognitive deficits as treatment targets in schizophrenia
JM Gold
SCHIZOPHRENIA RESEARCH (2004)
Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat
PD Shepard et al.
NEUROPSYCHOPHARMACOLOGY (2003)
The endophenotype concept in psychiatry: Etymology and strategic intentions
II Gottesman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Manipulation of brain kynurenines: Glial targets, neuronal effects, and clinical opportunities
R Schwarcz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia
S Erhardt et al.
NEUROSCIENCE LETTERS (2001)
Increased cortical kynurenate content in schizophrenia
R Schwarcz et al.
BIOLOGICAL PSYCHIATRY (2001)
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review
MA Geyer et al.
PSYCHOPHARMACOLOGY (2001)
分享论文
